UniProtKB/Swiss-Prot Q9UNE7 : Variant p.Met240Thr
E3 ubiquitin-protein ligase CHIP
Gene: STUB1
Feedback ?
Variant information
Variant position:
240
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Methionine (M) to Threonine (T) at position 240 (M240T, p.Met240Thr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and hydrophobic (M) to medium size and polar (T)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In SCAR16.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
240
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
303
The length of the canonical sequence.
Location on the sequence:
EKRKKRDIPDYLCGKISFEL
M REPCITPSGITYDRKDIEEH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EKRKKRDIPDYLCGKISFELM REPCITPSGITYDRKDIEEH
Mouse EKRKKRDIPDYLCGKISFELM REPCITPSGITYDRKDIEEH
Rat EKRKKRDIPDYLCGKISFELM REPCITPSGITYDRKDIEEH
Chicken EKRKKRDIPDYLCGKISFELM REPCITPSGITYDRKDIEEH
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 303
E3 ubiquitin-protein ligase CHIP
Domain
226 – 300
U-box
Region
143 – 303
Required for ubiquitination of FOXO1
Cross
221 – 221
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Cross
255 – 255
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis
260 – 260
H -> Q. Abolished E3 ubiquitin-protein ligase activity. Loss of ability to ubiquitinate FOXP3, RIPK1, RIPK3 and SIRT6. Abolishes STUB1-mediated degradation of CHRNA3. Abolishes autoubiquitination and ubiquitination of ICER-type isoforms of CREM. Reduces interaction, ubiquitination and proteasomal degradation of NFATC3. No effect on localization to the mitochondria following oxygen and glucose deprivation-induced cellular stress.
Literature citations
Phenotype and frequency of STUB1 mutations: next-generation screenings in Caucasian ataxia and spastic paraplegia cohorts.
Synofzik M.; Schuele R.; Schulze M.; Gburek-Augustat J.; Schweizer R.; Schirmacher A.; Kraegeloh-Mann I.; Gonzalez M.; Young P.; Zuechner S.; Schoels L.; Bauer P.;
Orphanet J. Rare Dis. 9:57-64(2014)
Cited for: VARIANTS SCAR16 ASP-79; THR-79; VAL-123 AND THR-240;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.